CRISPR has crossed another threshold. In July, the FDA expanded Casgevy—the first approved CRISPR therapy—to children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. The genetic scissors are no longer a laboratory promise. They are becoming medicine earlier in life—while safety, access and cost remain the next frontier.